Compare Abeona Therapeutics Inc (ABEO) vs Byrna Technologies Inc (BYRN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Byrna Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Byrna Technologies Inc trades at $6.02 (market cap $139.06M). The key difference: Abeona Therapeutics Inc is far larger — about 2.7× Byrna Technologies Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BYRN | |
|---|---|---|
Market Cap | $373.32M | $139.06M |
Sector | Health | Technology |
52-Week High | $7.23 | $32.30 |
52-Week Low | $4.17 | $4.96 |
Enterprise Value | $228.22M | $132.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BYRN trades at $7.08, up 1.58% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The company reported Q4 2025 EPS beat but a Q1 2026 miss, with revenue of $118.12M in 2025 and a net income margin of 7.3%. Recent news highlights strategic marketing expansions and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic given strong analyst buy ratings (71.4%) and a high price target upside, though risks include negative cash flow, ongoing legal investigations, and margin pressure from retail channel shifts. Earnings growth and successful execution of new initiatives are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →
